Gastric band is safe and effective at three years in a national study subgroup of non-morbidly obese patients

Abstract

Aim: To analyze the 3-year outcomes of lower body mass index (BMI) (<35 kg/cm2) adjustable gastric band (AGB) recipients across multiple sites in the French health insurance system. Methods: From prospectively collected data on a cohort of 517 morbidly obese Swedish Adjustable Gastric Band® (SAGB) patients (Clinical Trials Web database, #NCT01183975), a retrospective analysis of a subgroup of 29 low-BMI patients was conducted. Patients had a severe obesity-related comorbidity, had undergone a prior bariatric procedure requiring reintervention, or had a maximum adult BMI≥40. Safety (mortality, adverse events) and effectiveness (BMI change, excess weight loss [EWL, %], total body weight loss [%TBWL], quality of life [QoL], and comorbidities) were evaluated. Results: Multiple surgical teams/sites enrolled patients and performed SAGB procedures between September 2, 2007 and April 30, 2008. Of 29 low-BMI patients (mean age, 41.3 ± 10.3 years), 89.7% were female, and obesity duration was 13.6 ± 7.3 years. Mean BMI was 31.5 ± 3.7; there were 37 comorbidities in 15/29 patients. At 3-year follow-up, BMI was 29.4 ± 4.9 (mean change, -2.3 ± 6.2; P = 0.069); total cohort EWL, 7.3 ± 74.8%; TBWL, 6.2 ± 18.8%; BMI≥30 to <35 EWL, 38.8 ± 48.0%; there were 7 comorbidities in 15/29 patients (P < 0.031). There were 20 adverse events in 13 patients (44.8%); SAGBs were retained in 25/29 (86.2%) at 3 years. Conclusions: In a retrospective analysis of a subgroup of BMI<35 kg/cm2 patients, some following a prior bariatric procedure, SAGB was found to be safe and effective at 3-year follow-up.